IMMUCELL CORP /DE/
ICCCNasdaqHealthcare · In Vitro & In Vivo Diagnostic Substances · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $27.6M | $26.5M | $17.5M | $18.6M | $19.2M | $15.3M |
| Operating income | $1.6M | −$1.6M | −$5.7M | −$2.3M | $257,385 | −$1.4M |
| Net income | −$1.0M | −$2.2M | −$5.8M | −$2.5M | −$78,292 | −$1.0M |
| Total assets | $42.5M | $45.1M | $43.8M | $44.9M | $44.5M | $40.3M |
| Total liabilities | $15.5M | $17.6M | $18.8M | $14.5M | $11.9M | $12.1M |
| Equity | $27.1M | $27.5M | $25.0M | $30.4M | $32.6M | $28.3M |
| EPS (diluted) | $-0.12 | $-0.26 | $-0.75 | $-0.32 | $-0.01 | $-0.14 |
| Shares out. | 9.0M | 7.8M | 7.7M | 7.7M | 7.2M | 7.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 6.0%
- Net margin
- −3.8%
- Return on equity
- −3.8%
- Return on assets
- −2.4%
- Return on capital (ROCE)
- 4.3%
- Liabilities / assets
- 36.4%
- Debt / equity
- 0.57×
- Book value / share
- $3.01
- Revenue growth (YoY)
- 4.3%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 2.93safe
- Accruals / assets
- −8.3%clean
- Beneish M-Score
- -3.15normal
- Piotroski F-Score
- 7/9strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 warning● 6 good- Reported a net loss
- Operating margin is positive
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Knudsen Ejnar A IiiActivist (13D)Nov 20, 2025
- Srk Fund I, LpActivist (13D)Sep 17, 2024
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 10,435 | 1.0 | -42.6% |
| Apr 30, 2026 | 18,194 | 1.0 | -32.9% |
| Apr 15, 2026 | 27,130 | 1.0 | -20.8% |
| Mar 31, 2026 | 34,248 | 2.4 | +25.3% |
| Mar 13, 2026 | 27,331 | 2.0 | +71.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.